Researchers have uncovered new antibiotics which prevent bacteria from multiplying, offering a strategy to fight infections.
List view / Grid view
Filter the results
Antibiotics are a type of antimicrobial drug used in the treatment and prevention of bacterial infections.
A new technology developed by scientists combines small molecule screening methods with machine learning algorithms to identify novel antibiotics that inhibit ribosomes.
Drug Target Review explores research that suggests the microbiome could be a therapeutic target for major depressive disorder and what treatment options are now in the pipeline as a result of this association.
In an effort to address some of the more serious untreatable infections encountered by patients with cystic fibrosis, Calibr will collaborate with the Cystic Fibrosis Foundation on a two-year project.
Isolated components found in the Saussurea controversa plant have antimicrobial and regenerative properties which could lead to a treatment for bone diseases.
A compound that has antimicrobial properties has been found by researchers, which could be used to combat drug-resistant infections.
A novel peptide has been discovered that attacks gram negative bacteria at a previously unknown site of action which presents a promising lead substance for the development of a new antibiotic.
A team of researchers has uncovered the structure of a T-box regulatory mechanism in bacteria, which could aid in the development of novel antibiotics.
A study has revealed an enzyme in bacteria that produces a molecule which is toxic to other bacteria and shows promise as an antibiotic substitute.
A new family of synthetic antibiotics that possess broad anti-Gram-negative antimicrobial activity has been discovered.
Glycans, which are found in mucus, have the ability to regulate how microbes behave and could lead to new therapeutics.
A technique to 'trick' bacteria into revealing pores in their cell walls has been developed and targeting these could make antibiotics more effective.
New antibiotics could be designed by discovering the mechanism a weapon bacteria uses to vanquish their competitors.
Researchers have used a high-throughput screening method to test over 125,000 molecules and identify a new class of antibiotics.
It is predicted that there will be 70 new monoclonal antibody (mAb) biotherapeutics available by 2020.